Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
